ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerERG induces taxane resistance in castration-resistant prostate cancerThe Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.The interconnectedness of cancer cell signaling.Oncogene-mediated alterations in chromatin conformationForced Trefoil Factor Family Peptide 3 (TFF3) Expression Reduces Growth, Viability, and Tumorigenicity of Human Retinoblastoma Cell Lines.Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancerDistinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer CellsAndrogen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Genomic and biochemical insights into the specificity of ETS transcription factors.Nutrigenetics and prostate cancer: 2011 and beyond.TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer ProgressionIdentification of TDRD1 as a direct target gene of ERG in primary prostate cancer.The oncogene ERG: a key factor in prostate cancer.Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerPTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationTranscriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusionsERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
P2860
Q24628746-6C027989-5617-44EF-B904-2F54C6FEDDA3Q30602046-C0A8CCAF-660D-4BFB-AE4C-830264002072Q33702987-23EF94C1-7125-40C8-BCD6-95D5664CD0E4Q34580034-8D481E28-5147-4B40-9665-1C6B23A24AFEQ35669733-C81D8572-D90A-45E2-A688-8E5F10BB1E53Q36061468-5C65FEEA-8FAB-41DB-A90B-2C5B83577B45Q36132170-C966939B-8942-4F5A-B2B9-B5E0886D6469Q36304154-B682207C-3E81-4165-9CAE-98EA94269C20Q36848024-3BC6FC16-3D81-4B96-ACFC-91187F6AC88DQ37016134-66776F12-D05F-429C-8732-B56F92ED8BBDQ37157965-901C4332-6010-42F1-8634-DC53CEB6B5F4Q37727814-2CE06F50-21EC-4868-B1B8-7F33272629BAQ37872764-EC454248-75FF-4139-BD54-6B5290D8614EQ37885642-F82620A8-8850-42F2-A868-EE5004E76FF1Q38069582-8A8D1A34-8C2B-462A-BFDC-40184F991C15Q38318517-8A4881AD-00DD-445E-9F20-87DE1A89DEBCQ38444138-FEA32BB1-7E3D-46DE-8807-FBA7C2605601Q38503798-D59F2D24-4F5D-42DA-9093-5497E15D4D5AQ38657057-CD0C90F1-C277-4C84-9511-5863E0E9E071Q38938642-0E441D6D-CE2B-4CA7-999E-002AA07EB9D0Q39132148-27089880-27E7-4510-B215-D9146CEDFD73Q39164084-D43582D1-186A-4120-AD7F-771CA65DFC3CQ39437808-DE02B206-D4F4-47FA-B921-CDBFCD7D88E0Q41467986-48E05BC1-A2C9-4534-A5E9-D004F20DB47FQ41660235-EBA792C9-A38C-44FA-8EEA-22E8815ACCFDQ41879186-23BB3A9B-A168-481D-AC6E-6C8788241E13Q41889452-304D2B7A-EF16-49E6-83D7-9D1C95864246Q41988183-F700C2E2-1022-41FB-BD7B-DE90C4C1AB30Q42173139-CAF38771-9CC4-4B67-96C8-D6FFA8BB9E7CQ45789503-CFBE744A-0579-4A9A-8076-DD5C6837DE3E
P2860
ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ERG cooperates with androgen r ...... te cancer disease progression.
@ast
ERG cooperates with androgen r ...... te cancer disease progression.
@en
ERG cooperates with androgen r ...... te cancer disease progression.
@nl
type
label
ERG cooperates with androgen r ...... te cancer disease progression.
@ast
ERG cooperates with androgen r ...... te cancer disease progression.
@en
ERG cooperates with androgen r ...... te cancer disease progression.
@nl
prefLabel
ERG cooperates with androgen r ...... te cancer disease progression.
@ast
ERG cooperates with androgen r ...... te cancer disease progression.
@en
ERG cooperates with androgen r ...... te cancer disease progression.
@nl
P2093
P2860
P356
P1433
P1476
ERG cooperates with androgen r ...... te cancer disease progression.
@en
P2093
Arul M Chinnaiyan
Christopher J Lafargue
David S Rickman
Kanishka Sircar
Kirsten D Mertz
Samprit Banerjee
Sunita R Setlur
Sven Perner
Tarek A Bismar
P2860
P304
P356
10.1593/NEO.10866
P577
2010-12-01T00:00:00Z